£550K
The oversubscribed funding round was led by SFC Capital to support clinical expansion and regulatory progress for the firm's memory testing platform.
"Many new therapies for Alzheimer’s disease and related conditions are designed to work at the earliest stages of the disease process. However, most existing cognitive tests detect impairment only once irreversible damage has already occurred. Our test shifts the detection window years earlier, providing a far more sensitive way of identifying subtle changes in memory."
.png)
SFC Capital + 4 others
.png)